KASEB-MDACC-PERIOPERATIVE
Regimen
- Experimental
- perioperative nivolumab + ipilimumab
- Control
- perioperative nivolumab monotherapy
Population
Resectable hepatocellular carcinoma
Key finding
ORR 23% (nivo-mono) vs 0% (nivo+ipi) by RECIST; MPR 23% vs 21%. Combo had higher G3-4 AE. Small phase 2 — signal-generating for perioperative IO in resectable HCC.
Source: PMID 35065057